Literature DB >> 3179443

B protein of factor XIII: differentiation between free B and complexed B.

H Yorifuji1, K Anderson, G W Lynch, L Van de Water, J McDonagh.   

Abstract

Plasma factor XIII is a complex of A and B proteins noncovalently linked in a tetramer, A2B2, Enzyme-linked immunosorbent assays (ELISA) were developed to measure the separate factor XIII proteins and the complex. All of the A protein in plasma is in the zymogen complex. The B assay measures the total amount of B protein in plasma (both free B and complexed B). This was confirmed by nondenaturing gel electrophoresis and immunoblotting, which showed two bands for B in plasma with this antibody. Two assays were developed to measure A2B2 complex specifically. One assay used a monoclonal antibody to B to bind antigen and measured B protein in the zymogen complex only and hence the concentration of the complex. The specificity of this antibody was also shown by immunoblotting. In the second assay, the capture antibody was to B and the tag antibody was to A. These two assays gave identical results for the concentration of A2B2 (0.07 mumol/L, 21.6 micrograms/mL in normal plasma). Thus, for the first time, differentiation and quantitation of free B and complexed B in plasma was possible. The assays were used to measure factor XIII proteins in plasma from normal controls, homozygous-deficient factor XIII patients, and their heterozygous relatives. The normal concentration of A in plasma is 0.13 to 0.16 mumol/L (approximately 11 micrograms/mL), all of which is in A2B2. The total B concentration is 0.26 to 0.28 mumol/L (approximately 21 micrograms/mL), half of which is complexed. The free B concentration is 0.13 mumol/L (approximately 10 micrograms/mL). Homozygous-deficient patients have essentially no A protein, but their free B concentration is 0.11 mumol/L. Heterozygotes have decreased A2B2, but their free B is 0.11 mumol/L. These results indicate that the concentration of free B is remarkably constant and does not depend on the concentration of A2 or A2B2.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3179443

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

1.  Role of calcium in the conformational dynamics of factor XIII activation examined by hydrogen-deuterium exchange coupled with MALDI-TOF MS.

Authors:  Ricky T Woofter; Muriel C Maurer
Journal:  Arch Biochem Biophys       Date:  2011-05-26       Impact factor: 4.013

2.  Tridegin, a new peptidic inhibitor of factor XIIIa, from the blood-sucking leech Haementeria ghilianii.

Authors:  S Finney; L Seale; R T Sawyer; R B Wallis
Journal:  Biochem J       Date:  1997-06-15       Impact factor: 3.857

3.  Platelets stored at 4°C contribute to superior clot properties compared to current standard-of-care through fibrin-crosslinking.

Authors:  Prajeeda M Nair; Shaunak G Pandya; Shatha F Dallo; Kristin M Reddoch; Robbie K Montgomery; Heather F Pidcoke; Andrew P Cap; Anand K Ramasubramanian
Journal:  Br J Haematol       Date:  2017-06-04       Impact factor: 6.998

4.  The interaction between fibrinogen and zymogen FXIII-A2B2 is mediated by fibrinogen residues γ390-396 and the FXIII-B subunits.

Authors:  James R Byrnes; Clare Wilson; Anthony M Boutelle; Chase B Brandner; Matthew J Flick; Helen Philippou; Alisa S Wolberg
Journal:  Blood       Date:  2016-08-25       Impact factor: 22.113

5.  The Structure of Blood Coagulation Factor XIII Is Adapted to Oxidation.

Authors:  Alexandra Vasilyeva; Lyubov Yurina; Alexander Shchegolikhin; Maria Indeykina; Anna Bugrova; Alexey Kononikhin; Eugene Nikolaev; Mark Rosenfeld
Journal:  Biomolecules       Date:  2020-06-17

6.  New developments in the management of congenital Factor XIII deficiency.

Authors:  Zehra Fadoo; Quratulain Merchant; Karim Abdur Rehman
Journal:  J Blood Med       Date:  2013-05-28

Review 7.  Factor XIII-A: An Indispensable "Factor" in Haemostasis and Wound Healing.

Authors:  Fahad S M Alshehri; Claire S Whyte; Nicola J Mutch
Journal:  Int J Mol Sci       Date:  2021-03-17       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.